Following Ipilimumab, six anti-PD-1 (Nivolumab, Pembrolizumab, and Cemiplimab) or anti-PD-L1 (Atzolizumab, Avelumab, Durvalumab) antibodies have been granted FDA approval for the treatment of multiple cancer types, including melanoma, renal cell carcinoma, hepatocellular carcinoma, and Hodgkin’s disease [10,11]. Here, CD274 is linked to cancer.